https://www.selleckchem.com/products/rbn-2397.html
Heart failure (HF) with preserved ejection fraction (HFpEF) causes significant cardiovascular morbidity and mortality. It is a growing problem in the developed world, especially, in the aging population. There is a paucity of data on the treatment of patients with HFpEF. We aimed to identify pharmacotherapies that improve peak oxygen consumption (peak VO ), cardiovascular mortality, and HFhospitalizations in patients with HFpEF. We conducted a systematic literature search for English studies in PubMed, EMBASE, Cochrane Central Register
Like
Comment
Share
